Fount of Information

TriLink社 mRNA Vaccines - A New Era in Vaccinology

このセミナーに関するご照会・お問合せはこちら

TriLink_logo.png

mRNA_Vaccines_A_New_Era_in_Vaccinology.png

mRNA Vaccines – A New Era in Vaccinology

mRNA vaccines, propelled into public view in 2020 by their development for COVID-19, have actually had a relatively prolonged incubation period. While the first evidence for an mRNA vaccine dates back to a report by Martinon et al. in 1993, subsequent scientific progress was slow in the NIH’s PubMed database. More specifically, these articles did not appear until 2004 (Pascolo and collaborators; Cannon and Weissman), were followed by one in 2010 (Weiss et al.), and then several more per year until about 2015, when the number of annual reports noticeably increased... 

Read_More_FOI.PNG


Your Partner for mRNA Vaccine Development

The recent clinical success of mRNA vaccines against SARS-CoV-2 paves the way for future vaccine development. Whether you are in the discovery phase or nearing GMP manufacturing, TriLink offers a solution to fit your mRNA vaccine program:

·    Plasmid manufacturing for use as an IVT template

·    Custom mRNA synthesis from RUO through GMP grade

·    CleanCap® capping technology for non-replicating mRNA and self-amplifying mRNA

Learn more about how TriLink can support your vaccine development program.

mRNA Vaccine Solutions.PNG
 Learn_More_FOI.PNG

Fount of Information は、新商品、新規取扱メーカーなどの情報をいち早く紹介するコンテンツです。情報発信のスピードを重視しているコンテンツのため、現時点で法規制や取り扱いを確認できていない商品、定価を設定できていない商品があります。ご要望やご照会を受けた商品について、法令整備や在庫の充実を図ります。